RE: Vlad's reply to that tweet18 Nov 2020 15:11
Back with more shares than I had before my tamper tantrum lol ;-) it paid off, and with MCRO delivering +30% today I was happy to pay over the odds today.
Been saying for months this company needs cash for IND, thought it would be a placing in 2021 or cash from Eli Lilly.
This loan is better than a placing.
Is it better than cash from Eli Lilly? IMO Yes, there is no waiting, no strings attached and negotiations with Eli can begin from a position of strength. Hemogenyx are not dependant on Eli Lilly any more, they dont need up front cash, they are in no rush to sign a sub optimal licencing agreement. Eli have said time and again they are happy with progress and just trying to decide WHICH antibody to licence, but if they are not willing to pay a fair price? Hemo dont have to accept what they are offered out of desperation any more :-)